抗真菌药物新进展
|
摘要
按照化学结构分类简要介绍抗真菌药物的作用机制、药效学、独特的药代动力学以及目前相关指南对于曲霉病、念珠菌病等的管理。重点介绍了三种新上市的抗真菌药物,如艾沙康唑、艾氟康唑、Tavaborole。也介绍了某些抗真菌药物所具有的非抗真菌作用。
In the paper,according to the chemical structure of antifungal agents,the mechanism of action,pharmacodynamics,unique pharmacokinetic and the current guidelines for the management of aspergillosis,candidiasis etc were briefly introduced. Three kinds of new antifungal drugs,namely,Isavuconazonium,Efinaconazole and Tavaborole were particularly demonstrated. The non-antifungal effects of some antifungal agents were also introduced.
In the paper,according to the chemical structure of antifungal agents,the mechanism of action,pharmacodynamics,unique pharmacokinetic and the current guidelines for the management of aspergillosis,candidiasis etc were briefly introduced. Three kinds of new antifungal drugs,namely,Isavuconazonium,Efinaconazole and Tavaborole were particularly demonstrated. The non-antifungal effects of some antifungal agents were also introduced.
引文
[1]王爱平,李若瑜.系统抗真菌药物概述[J].中国药物评价,2012,29(1):10-13.
[2]Richardson MD,Warnock.fungal infection:Diagnosis and management[M].Second edition.USA:Blackwell Science Inc,1997.
[3]Pappas PG,Kauffman CA,Andes DR,et al.Clinical practice guideline for the management of candidiasis:2016 update by the infectious diseases society of America[J].Clin Infect Dis,2016,62(4):e1-e50.
[4]Patterson TF,Thompson GR 3rd,Denning DW,et al.Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the infectious diseases society of America[J].Clin Infect Dis,2016,63(4):e1-e60.
[5]Perfect JR,Dismukes WE,Dromer F,et al.Clinical practice guidelines for the management of cryptococcal disease:2010update by the infectious diseases society of America[J].Clin Infect Dis,2010,50(3):291-322.
[6]曲卉,李若瑜,余进,等.抗真菌药物在皮肤黏膜利什曼病治疗中的应用[J].实用皮肤病学杂志,2015,8(2):115-118.
[7]卢鑫,孙文逵,施毅.抗真菌药物雾化吸入研究进展[J].中国感染与化疗杂志,2012,12(1):67-70.
[8]顾卫青,朱江,董先红.广谱唑类抗真菌新药艾沙康唑[J].中国药师,2016,19(1):166-168.
[9]宋海超,张旭,霍彩霞.硫酸艾沙康唑鎓合成工艺的研究进展[J].国际药学研究杂志,2016,43(3):436-440,444.
[10]Poulakos M,Grace Y,Machin JD,et al.Efinaconazole and tavaborole:emerging antifungal alternatives for the topical treatment of onychomycosis[J].Journal of Pharmacy Practice,2017,30(2)245-255.
[11]唐教清,陈爽,穆潺,等.伊曲康唑的非抗真菌作用研究进展[J].中华医学杂志,2016,96(30):2442-2445.
[12]吴玮峰,张晔.抗真菌上市新药及其合成评述[J].中国药师,2011,14(8):1203-1206.
[13]夏家栋.福司氟康唑合成方法研究进展[J].广东化工,2015,42(309):95-96,110.
[14]Queiroz-Telles F,de Hoog S,Santos DW,et al.Chromoblastomycosis[J].Clin Microbiol Rev,2017,30(1):233-276.
[15]陈祖基.新型抗真菌药物在眼科的研究进展[J].眼科研究,2007,25(8):629-633.
[16]孙禾,苏欣,徐小雾,等.泊沙康唑临床应用研究进展[J].中国感染与化疗杂志,2012,12(3):230-232.
[17]王爱平.舍他康唑抗炎活性研究进展[J].中国真菌学杂志,2014,9(2):111-113.
[18]王爱平,李若瑜.2%酮康唑乳膏在皮肤科疾病中的应用[J].中国真菌学杂志,2010,5(3):179-183.
[19]Bolognia JL.朱学骏,王宝玺,项蕾红,等译.Bolognia皮肤病学[M].北京:北京大学医学出版社,2011:209-223,2395-2398.
[20]王爱平,刘雯,金岚,等.2%利拉萘酯乳膏治疗足癣和体股癣疗效和安全性评价[J].中国真菌学杂志,2007,2(2):107-110.
[21]王爱平,李若瑜.5%盐酸阿莫罗芬搽剂在甲真菌病中的应用[J].中国真菌学杂志,2015,10(5):317-320.
[22]Saunders J,Maki K,Koski R,et al.Tavaborole,efinaconazole,and luliconazole:Three new antimycotic agents for the treatment of dermatophytic fungi[J].J Pharm Pract,2016,Aug 3.pii:0897190016660487.[Epub ahead of print].
[23]朱育菁,于晓杰,潘志针,等.灰黄霉素的研究进展[J].厦门大学学报(自然科学版),2010,49(3):435-439.
[2]Richardson MD,Warnock.fungal infection:Diagnosis and management[M].Second edition.USA:Blackwell Science Inc,1997.
[3]Pappas PG,Kauffman CA,Andes DR,et al.Clinical practice guideline for the management of candidiasis:2016 update by the infectious diseases society of America[J].Clin Infect Dis,2016,62(4):e1-e50.
[4]Patterson TF,Thompson GR 3rd,Denning DW,et al.Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the infectious diseases society of America[J].Clin Infect Dis,2016,63(4):e1-e60.
[5]Perfect JR,Dismukes WE,Dromer F,et al.Clinical practice guidelines for the management of cryptococcal disease:2010update by the infectious diseases society of America[J].Clin Infect Dis,2010,50(3):291-322.
[6]曲卉,李若瑜,余进,等.抗真菌药物在皮肤黏膜利什曼病治疗中的应用[J].实用皮肤病学杂志,2015,8(2):115-118.
[7]卢鑫,孙文逵,施毅.抗真菌药物雾化吸入研究进展[J].中国感染与化疗杂志,2012,12(1):67-70.
[8]顾卫青,朱江,董先红.广谱唑类抗真菌新药艾沙康唑[J].中国药师,2016,19(1):166-168.
[9]宋海超,张旭,霍彩霞.硫酸艾沙康唑鎓合成工艺的研究进展[J].国际药学研究杂志,2016,43(3):436-440,444.
[10]Poulakos M,Grace Y,Machin JD,et al.Efinaconazole and tavaborole:emerging antifungal alternatives for the topical treatment of onychomycosis[J].Journal of Pharmacy Practice,2017,30(2)245-255.
[11]唐教清,陈爽,穆潺,等.伊曲康唑的非抗真菌作用研究进展[J].中华医学杂志,2016,96(30):2442-2445.
[12]吴玮峰,张晔.抗真菌上市新药及其合成评述[J].中国药师,2011,14(8):1203-1206.
[13]夏家栋.福司氟康唑合成方法研究进展[J].广东化工,2015,42(309):95-96,110.
[14]Queiroz-Telles F,de Hoog S,Santos DW,et al.Chromoblastomycosis[J].Clin Microbiol Rev,2017,30(1):233-276.
[15]陈祖基.新型抗真菌药物在眼科的研究进展[J].眼科研究,2007,25(8):629-633.
[16]孙禾,苏欣,徐小雾,等.泊沙康唑临床应用研究进展[J].中国感染与化疗杂志,2012,12(3):230-232.
[17]王爱平.舍他康唑抗炎活性研究进展[J].中国真菌学杂志,2014,9(2):111-113.
[18]王爱平,李若瑜.2%酮康唑乳膏在皮肤科疾病中的应用[J].中国真菌学杂志,2010,5(3):179-183.
[19]Bolognia JL.朱学骏,王宝玺,项蕾红,等译.Bolognia皮肤病学[M].北京:北京大学医学出版社,2011:209-223,2395-2398.
[20]王爱平,刘雯,金岚,等.2%利拉萘酯乳膏治疗足癣和体股癣疗效和安全性评价[J].中国真菌学杂志,2007,2(2):107-110.
[21]王爱平,李若瑜.5%盐酸阿莫罗芬搽剂在甲真菌病中的应用[J].中国真菌学杂志,2015,10(5):317-320.
[22]Saunders J,Maki K,Koski R,et al.Tavaborole,efinaconazole,and luliconazole:Three new antimycotic agents for the treatment of dermatophytic fungi[J].J Pharm Pract,2016,Aug 3.pii:0897190016660487.[Epub ahead of print].
[23]朱育菁,于晓杰,潘志针,等.灰黄霉素的研究进展[J].厦门大学学报(自然科学版),2010,49(3):435-439.